FDA Standard Drug Review Goals Could be Lengthened By 1-2 Months, IG Says
This article was originally published in The Tan Sheet
Executive Summary
FDA should consider extending by one or two months its 10-month goal for standard drug reviews, the HHS Inspector General said in a 1report released March 25
You may also be interested in...
John Taylor Temporarily Replaces Sharfstein As FDA's Second-In-Command
John Taylor, counselor to FDA Commissioner Margaret Hamburg, will serve temporarily as second-in-command while Hamburg considers how to reorganize the agency's leadership following Principal Deputy Commissioner Josh Sharfstein's departure.
FDA “Refuse-To-File” Decisions Encouraged For Incomplete, Poor NDAs – IG
FDA should consider issuing "refuse-to-file" decisions more often for incomplete or inadequate NDAs, the HHS Inspector General recommended in a report released March 25
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC